RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000077.xml
PDF herunterladen
Semin Thromb Hemost 2003; 29(2): 185-194
DOI: 10.1055/s-2003-38834
DOI: 10.1055/s-2003-38834
Inherited Thrombophilia and Gestational Vascular Complications
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
23. April 2003 (online)
ABSTRACT
Severe obstetric complications, including preeclampsia, intrauterine growth retardation, abruptio placentae, and stillbirth, constitute a major cause of maternal and perinatal morbidity and death. The etiology of these severe obstetric complications is still unknown. However, the frequent finding of structural and thrombotic changes in placental capillaries, which lead to inadequate fetomaternal circulation and decreased placental perfusion, and the high prevalence of heritable or acquired risk factors for thrombosis found in women with these complications strongly suggest a cause-and-effect relationship. This review describes the recent findings on the association between these obstetric complications and the various thrombophilias, and recent therapeutic approaches. Aspirin, which was regarded as the drug of choice for the prevention of such obstetric complications, has proved to be ineffective in a large clinical trial. The encouraging observations on the efficacy of low-molecular-weight heparins, which are also included in the recently published guidelines of The American College of Chest Physicians, are summarized in this review. However, controlled clinical trials are still necessary to allow the development of better clinical standards.
KEYWORDS
Pregnancy - thrombophilia - obstetric complications - preeclampsia - low-molecular-weight heparin
REFERENCES
- 1 Roberts J M, Taylor R N, Musici T J. et al . Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol . 1989; 161 1200-1204
- 2 Salafia C M, Pezzulo J C, Lopez-Zeno J A, Minior V K, Vintzileos A M. Placental pathologic features of preterm preeclampsia. Am J Obstet Gynecol . 1995; 173 1079-1105
- 3 Shanklin D R, Sibai B M. Ultrastructural aspects of preeclampsia. Am J Obstet Gynecol . 1989; 161 735-741
- 4 Khong T Y, Pearce J M, Robertson W B. Acute atherosis in preeclampsia: maternal determination and fetal outcome in the presence of the lesion. Am J Obstet Gynecol . 1987; 157 360-363
- 5 Salafia C M, Minior V K, Pezzulo J C. et al . Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathologic features. Am J Obstet Gynecol . 1995; 173 1049-1057
- 6 Green J R. Placenta previa and abruptio placentae. In: Creasy RK, Resnik R, eds. Maternal Fetal Medicine: Principles and Practice Philadelphia: Saunders 1994: 609-610
MissingFormLabel
- 7 Redman C WG, Sacks G P, Sargent I L. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol . 1999; 180 499-506
- 8 Dahlbäck B. Molecular genetics of venous thromboembolism. Ann Intern Med . 1995; 27 187-192
- 9 Bertina R M. Genetic approach to thrombophilia. Thromb Haemost . 2001; 86 92-103
- 10 Conard J, Horellou M H, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost . 1990; 63 319-320
- 11 De Stefano V, Leone G, Mastrangelo S. et al . Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost . 1994; 71 799-800
- 12 Bertina R M, Koeleman B P, Köster T. et al . Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature . 1994; 369 64-67
- 13 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. Common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood . 1996; 88 3698-3703
- 14 Frosst P, Blom H J, Milos R. et al . A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet . 1995; 10 111-113
- 15 Glueck C J, Wang P, Fontaine R N. et al . Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism . 1999; 48 1589-1595
- 16 Glueck C J, Phillips H, Cameron D. et al . The 4G/4G polymorphism of the hypofibrinolytic PAI-1 gene: an independent risk factor for serious pregnancy complications. Metabolism . 2000; 49 845-852
- 17 Lockshin M D. Pregnancy loss in the antiphospholipid syndrome. Thromb Haemost . 1999; 82 641-648
- 18 Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost . 1997; 78 297-301
- 19 Greer I A. Epidemiology, risk factors and prophylaxis of venous thrombo-embolism in obstetrics and gynaecology. Clin Obstet Gynaecol . 1997; 11 403-430
- 20 Greer I A. Thrombosis in pregnancy: maternal and fetal issues. Lancet . 1999; 353 1258-1265
- 21 Greer I A. The challenge of thrombophilia in maternal-fetal medicine. N Engl J Med . 2000; 342 424-425
- 22 Finazzi G, Barbui T. Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C and protein S. Thromb Haemost . 1994; 71 15-18
- 23 Friederich P W, Sanson B J, Simioni P. et al . Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med . 1996; 125 955-960
- 24 Clark P, Brennand J, Conkie J A. et al . Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost . 1998; 79 1166-1170
- 25 Hallak M, Senderowicz J, Cassel A. et al . Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol . 1997; 176 889-893
- 26 Bokarewa M I, Bremme K, Blombäck M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol . 1996; 92 473-478
- 27 Shu H, Wramsby M, Bokarewa M, Blombäck M, Bremme K. Decrease in protein C inhibitor activity and acquired APC resistance during normal pregnancy. J Thromb Thrombolysis . 2000; 9 277-281
- 28 Martinelli I, Sacchi E, Landi G. et al . High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med . 1998; 338 1793-1797
- 29 Kupferminc M J, Eldor A, Steinman N. et al . Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med . 1999; 340 9-13
- 30
den Heijer M, Köster T, Blom H J. et al .
Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.
N Engl J Med .
1996;
334
759-762
MissingFormLabel
- 31 McColl M D, Ellison J, Reid F. et al . Prothrombin 20210 G→A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. Br J Obstet Gynaecol . 2000; 107 565-569
- 32 Lindqvist P G, Svensson P J, Dahlbäck B, Marsal K. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss-a possible evolutionary selection mechanism. Thromb Haemost . 1998; 79 69-73
- 33 Glueck C J, Kupferminc M J, Fontaine R N. et al . Increased frequency of the hypofibrinolytic 4G/4G polymorphism of the plasminogen activator inhibitor-1 (PAI-1) gene in women with obstetric complications. Obstet Gynecol . 2001; 97 44-48
- 34 de Vries I J, Dekker G A, Huijgens P C. et al . Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol . 1997; 104 1248-1254
- 35 Goddijn-Wessel T A, Wouters M G, van de Molen F E. et al . Hyperhomocysteinemia: a risk factor for placental abruption or infarction. Eur J Obstet Gynecol Reprod Biol . 1996; 66 23-29
- 36 Vollsett S E, Bjorke-Monsen A AL, Igrens L M. Plasma total homocysteine and previous pregnancies: the Hordaland homocysteine study. Proceedings of the 2nd International Symposium on Homocysteine (Abst). Neth J Med . 1998; 52 S54
- 37 Van der Molen F E, Verbrüggen B, Novakova I. et al . Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy. Br J Obstet Gynaecol . 2000; 107 785-791
- 38 Pabinger I, Grafenhofer H, Kaider A. et al . Preeclampsia and fetal loss in women with a history of venous thromboembolism. Arterioscler Thromb Vasc Biol . 2001; 21 874-879
- 39 Vern T Z, Alles A J, Kowal-Vern A, Longtine J, Roberts D J. Frequency of factor V (Leiden) and prothrombin G20210A in placentas and their relationship with placental lesions. Hum Pathol . 2000; 31 1036-1043
- 40 Dekker G A, de Vries I P J, Doelitzsch P M. et al . Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol . 1995; 173 1042-1048
- 41 Dizon-Townson D S, Nelson L M, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol . 1996; 175 902-905
- 42 Grandone E, Margaglione M, Colaizzo D. et al . Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost. 1997; 77 1052-1054
- 43 Nagy B, Toth T, Rigo Jr J. et al . Detection of factor V Leiden in severe pre-eclamptic Hungarian women. Clin Genet . 1998; 53 478-481
- 44 Rajkovic A, Catlano P M, Malinow M R. Elevated homocysteine levels with preeclampsia. Obstet Gynecol . 1997; 90 168-171
- 45 Sohda S, Arinami T, Hamada H M. et al . Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet . 1997; 34 525-526
- 46 Kupferminc M J, Fait G, Many A. et al . Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol . 2000; 96 45-49
- 47 Rigo Jr J, Nagy B, Fintor L. et al . Maternal and neonatal outcome of preeclamptic pregnancies: the potential roles of factor V Leiden mutation and 5,10 methylenetetrahydrofolate reductase. Hypertens Pregnancy . 2000; 19 163-172
- 48 Mello G, Parretti E, Martini E. et al . Usefulness of screening for congenital or acquired hemostatic abnormalities in women with previous complicated pregnancies. Haemostasis . 1999; 29 197-203
- 49 Lindoff C, Ingemarsson I, Martinsson G. et al . Preeclampsia is associated with reduced response to activated protein C. Am J Obstet Gynecol . 1997; 176 457-460
- 50 O'Shaughnessy K M, Fu B, Ferraro F. et al . Factor V Leiden and thermolabile methylenetetrahydrofolate reductase gene variants in an east Anglian preeclampsia cohort. Hypertension . 1999; 33 1338-1341
- 51 Powers R W, Minich L A, Lykins D L. et al . Methylenetetrahydrofolate reductase polymorphism, folate, and susceptibility to preeclampsia. J Soc Gynecol Invest . 1999; 6 74-79
- 52 Krauss T, Augustin H G, Osmers R. et al . Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol . 1998; 92 457-460
- 53 Lindqvist P G, Svensson P J, Marsaal K. et al . Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost . 1999; 81 532-537
- 54 Kupferminc M J, Fait G, Many A. et al . Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol. . 2000; 96 45-49
- 55 Infante-Rievard C, David M, Gauthier R, Rivard G E. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study. N Engl J Med . 1991; 325 1063-1066
- 56 Lima F, Khamashta M A, Buchanan N M. et al . A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol . 1996; 14 131-136
- 57 Dizon-Townson D S, Meline L, Nelson L M, Varner M, Ward K. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol . 1997; 177 402-405
- 58 Grandone E, Margaglione M, Colaizzo D. et al . Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost . 1997; 77 822-824
- 59 Brenner B, Mandel H, Lanir N. et al . Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol . 1997; 97 551-554
- 60 Brenner B, Sarig G, Weiner Z. et al . Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost . 1999; 82 6-9
- 61 Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis J S. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost . 2000; 83 693-697
- 62 Preston F E, Rosendaal F R, Walker I D. et al . Increased fetal loss in women with heritable thrombophilia. Lancet . 1996; 348 913-916
- 63 Sanson B J, Friederich P W, Simioni P. et al . The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost . 1996; 75 387-388
- 64 Ridker P M, Miletich J P, Buring J E. et al . Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med . 1998; 128 1000-1003
- 65 Deitcher S R, Park V M, Kutteh W H. Prothrombin 20210 GA mutation analysis in Caucasian women with early first trimester recurrent pregnancy loss (Abst). Blood . 1998; 92(Suppl 1) 118b
- 66 Durnwald C P, Flora R, Agamanolis D. et al . Hereditary thrombophilia as a cause of fetal loss. Obstet Gynecol . 2000; 95 S11-S12
- 67 Yamada H, Kato E H, Ebina Y. et al . Factor XII deficiency in women with recurrent miscarriage. Gynecol Obstet Invest . 2000; 49 80-83
- 68 Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E. Resistance to activated protein C and the Leiden mutation: high prevalence in patients with abruptio placentae. Am J Obstet Gynecol . 1998; 179 1565-1567
- 69 Kupferminc M J, Peri H, Zwang E. et al . High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss. Acta Obstet Gynecol Scand . 2000; 11 963-967
- 70 Arias F, Romero R, Joist H, Kraus F T. Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. J Matern Fetal Med . 1998; 7 277-286
- 71 Kupferminc M J, Many A, Rosner S. et al . Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Am J Obstet Gynecol . 2000; 182(1 Part 2) Abst
- 72 Mousa H A, Alfirevic Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome?. Hum Reprod . 2000; 15 1830-1833
- 73 Caritis S, Sibai B, Hauth J. et al . Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med . 1998; 338 701-705
- 74 Kutteh W H, Ermel L D. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol . 1996; 35 402-407
- 75 Harenberg J, Schneider D, Heilmann L, Wolf H. Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Haemostasis . 1993; 23 314-320
- 76 Ginsberg J S, Hirsh J. Use of antithrombotic agents during pregnancy. Chest . 1998; 114(5 Suppl) 524S-530S
- 77 Gris J C, Neveu S, Tailand M L. et al . Use of low-molecular-weight heparin (enoxaparin) or of a phenformin-like substance (moroxydine chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity. Thromb Haemost . 1995; 73 362-367
- 78 Brenner B. Inherited thrombophilia and pregnancy loss. Thromb Haemost . 1999; 82 634-640
- 79 Younis J S, Ohel G, Brenner B. et al . The effect of thromboprophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. Br J Obstet Gynaecol . 2000; 107 415-419
- 80 Bar J, Cohen-Sacher B, Hod M. et al . Low-molecular-weight heparin for thrombophilia in pregnant women. Int J Gynaecol Obstet . 2000; 69 209-213
- 81 Rai R, Cohen H, Dave M, Regan L: Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J . 1997; 314 253-254
- 82 Kupferminc M J, Fait G, Many A. et al . Low molecular weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy . 2001; 20 35-44
- 83 Riyazi N, Leeda M, de Vries I J. et al . Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol . 1998; 80 49-54
- 84 Leeda M, Riyazi N, de Vries I J. et al . Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction. Am J Obstet Gynecol . 1998; 179 135-139
- 85 Ginsberg J S, Greer I A, Hirsh J. Use of antithrombotic agents during pregnancy. Chest . 2001; 119(Suppl) 122S-131S
- 86 Branch D W, Peaceman A M, Druzin M. et al . A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. Am J Obstet Gynecol . 2000; 182 122-127